PureTech spins out Celea with $180M to test next-gen IPF drug
What's the deal? Celea TherapeuticsDealroom has a profile for this one. Try Dealroom → has raised $180 million to advance deupirfenidone, an experimental treatment for idiopathic pulmonary fibrosis (IPF). The financing capitalises a newly spun-out PureTech Health entity and will fund a global Phase 3 trial.
Who's backing it? The syndicate includes RA Capital and Leaps by BayerDealroom has a profile for this one. Try Dealroom →, alongside a large US healthcare fund and a sovereign wealth fund.
What's the endgame? Proceeds fund SURPASS-IPF, billed as the first industry-sponsored Phase 3 trial directly comparing an investigational IPF therapy with an approved one. Deupirfenidone, a deuterated form of pirfenidone, will be tested head-to-head against approved pirfenidone. The trial is due to start in the third quarter of 2026, with change in forced vital capacity at 52 weeks as its primary endpoint.
Why now? Current antifibrotics — pirfenidone and nintedanib — are effective but limited by side-effects that hurt tolerability and adherence. A next-generation version with better tolerability could be commercially meaningful if the data hold up.
What's in it for PureTech? The deal transfers the asset into Celea and lifts the post-money valuation to about $302.5 million. PureTech retains a 35.4% stake and structures upside through royalties and up to $190 million in sales milestones.
What could go wrong? The financing's significance hinges on whether SURPASS-IPF can show clear superiority over a well-established branded comparator. Head-to-head trials against an incumbent standard of care raise the bar.
The signal: The raise is a rare, heavily backed, late-stage respiratory financing at a time when investors are deploying targeted rather than broad capital into biotech. It also marks a structured value-creation move for PureTech, crystallising worth from an asset it developed.
Read more: celeatx.com
